Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi

Hematological Oncology
Stefano LuminariMichele Spina

Abstract

The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF <50% (12%). Based on the intent to treat analysis, overall response rate was 72%, including 28 patients in complete remission (complete remission rate, 56%), and 8 in partial remission (16%). At the end of treatment, grades 3 to 4 cardiac events were observed in 6 patients. No significant modifications from baseline values of LVEF were observed during treatment and follow-up. Nonpegylated liposomal doxorubicin instead of doxorubicin in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)...Continue Reading

References

Jul 1, 1971·Circulation·B Lown, M Wolf
Dec 30, 1999·The New England Journal of Medicine·L F HutchinsK S Albain
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Feb 4, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LimatJ Y Cahn
Feb 19, 2005·Seminars in Oncology·Theresa M Allen, Francis J Martin
Feb 19, 2005·Seminars in Oncology·Michael S EwerAlberto A Gabizon
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Oct 3, 2007·Hematology/oncology Clinics of North America·Bruce D Cheson
Jun 24, 2008·Leukemia & Lymphoma·Giuseppe VisaniAlessandro Isidori
Jun 16, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·M MianM Fiegl

❮ Previous
Next ❯

Citations

Jun 30, 2019·Current Hematologic Malignancy Reports·Murali KesavanGraham P Collins
Jul 25, 2019·Current Opinion in Oncology·Pierre-Louis Soubeyran, Raul Cordoba
Aug 23, 2020·Current Oncology Reports·Pamela Allen
Feb 8, 2019·Future Oncology·Pieternella J LugtenburgStefano Luminari
Mar 11, 2021·Therapeutics and Clinical Risk Management·Barbara Jezeršek NovakovićAleksander Novaković
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashley E RoskoHeidi D Klepin
Jun 5, 2021·Critical Reviews in Oncology/hematology·Carlo ViscoMauro Krampera
Mar 14, 2021·British Journal of Haematology·Raul CordobaToby A Eyre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.